BRITISH JOURNAL OF HAEMATOLOGY

Volume 113, Issue 1, April 2001

IMAGES IN HAEMATOLOGY

1 **Sweet's syndrome after granulocyte colony-stimulating factor administration for refractory myelodysplastic syndrome**
T. Matsumura and M. Kami

2 **Erythrophagocytosis**
S. J. Harrison and E. Simpson

ANNOTATION

3 **The Leukaemia Research Fund/United Kingdom Cancer Cytogenetics Group Karyotype Database in acute lymphoblastic leukaemia: a valuable resource for patient management**
C. J. Harrison, M. Martineau and L. M. Secker-Walker

REVIEW

11 **Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory**
T. L. Holyoake

GUIDELINE

24 **Guidelines for the clinical use of red cell transfusions**
M. F. Murphy, T. B. Wallington, P. Kelsey, F. Boulton, M. Bruce, H. Cohen, J. Duguid, S. M. Knowles, G. Poole and L. M. Williamson

TRANSFUSION MEDICINE

32 **A DNA-based immunization protocol to produce monoclonal antibodies to blood group antigens**
T.-H. Tearina Chu, G. R. Halverson, K. Yazdanbakhsh, R. Øyen and M. E. Reid

Short reports

37 **Residual risk of transfusion in Ghana**
D. Candotti, F. Sarkodie and J.-P. Allain

40 **Provision of platelet support for fetuses and neonates affected by severe fetomaternal alloimmune thrombocytopenia**
E. Ranasinghe, J. D. Walton, C. M. Hurd, L. Saul, G. Smith, K. Campbell and W. H. Ouwehand

ERYTHROCYTES

43 **Molecular characterization of the *PK-LR* gene in sixteen pyruvate kinase-deficient patients**
A. Zanella, P. Bianchi, E. Fermo, A. Iurlo, M. Zappa, C. Vercellati, C. Boschetti, L. Baronciani and F. Cotton

Short report

49 **Erythropoietin synthesis by tumour tissues in a patient with uterine myoma and erythrocytosis**
M. Suzuki, S. Takamizawa, K. Nomaguchi, S. Suzu, M. Yamada, T. Igarashi and I. Sato

BONE MARROW HYPOPLASIA

52 **Decreased expression of transcription factor GATA-2 in haematopoietic stem cells in patients with aplastic anaemia**
S.-i. Fujimaki, H. Harigae, T. Sugawara, N. Takasawa, T. Sasaki and M. Kaku

PLATELETS, HAEMOSTASIS AND THROMBOSIS

58 **The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation**
R. Fuge, J. M. Bird, A. Fraser, D. Hart, L. Hunt, J. M. Cornish, N. Goulden, A. Oakhill, D. H. Pamphilon, C. G. Steward and D. I. Marks

65 **Greater inhibition of platelet procoagulant activity by antibody-derived glycoprotein IIb-IIIa inhibitors than by peptide and peptidomimetic inhibitors**
B. Lages and H. J. Weiss

72 **Polymorphonuclear leucocytes mediate endogenous thrombus lysis via a u-PA-dependent mechanism**
E. Moir, N. A. Booth, B. Bennett and L. A. Robbie

81 **Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity**
R. Ljung, P. Petrini, L. Tengborn and E. Sjörin

87 **Clinical spectrum of hepatitis C-related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease**
S. Lethagen, A. Widell, E. Berntorp, H. Verbaan and S. Lindgren

94 **Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever**
E. C. M. van Gorp, M. C. Minnema, C. Suharti, A. T. A. Mairuhu, D. P. M. Brandjes, H. ten Cate, C. E. Hack and J. C. M. Meijers

Short report 100 **Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease**
S. Fontana, H. E. Gerritsen, J. Kremer Hovinga, M. Furlan and B. Lämmle

HAEMATOLOGICAL MALIGNANCY

103 **Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol**
I. Hann, A. Vora, G. Harrison, C. Harrison, O. Eden, F. Hill, B. Gibson and S. Richards on behalf of the UK Medical Research Council's Working Party on Childhood Leukaemia

115 **Drug monitoring of low-dose PEG-asparaginase (Oncaspar™) in children with relapsed acute lymphoblastic leukaemia**
J. P. Vieira Pinheiro, H. J. Müller, D. Schwabe, M. Gunkel, J. Casimiro da Palma, G. Henze, V. von Schütz, M. Winkelhorst, G. Würthwein and J. Boos

120 **Cytogenetic risk groups in acute myeloblastic leukaemia differ greatly in their semi-solid colony growth**
L. Öhler, A. Berer, D. Aletaha, E. Kabrna, G. Heinze, B. Streubel, C. Fonatsch, O. A. Haas, K. Lechner and K. Geissler

126 **The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI**
D. Soligo, F. Servida, D. Delia, E. Fontanella, G. Lamorte, L. Caneva, R. Fumiatti and G. Lambertenghi Deliliers

136 **Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission**
A. Guarini, M. Breccia, E. Montefusco, M. Concetta Petti, A. Zepparoni, A. Vitale and R. Foa

143 **Molecular characterization of a myelodyspasia-associated chromosome 7 inversion**
R. Todd, B. Bia, E. Johnson, C. Jones and F. Cotter

153 **Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukaemia: implications for successful treatment and possible therapeutic strategies**
O. Yamada, M. Ichikawa, T. Okamoto, C. Park, T. Motoji, H. Mizoguchi and A. Shibuya

161 **Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease**
A. Martín, M. C. Fernández-Jiménez, M. D. Caballero, M. A. Canales, J. A. Pérez-Simón, J. García de Bustos, L. Vázquez, F. Hernández-Navarro and J. F. San Miguel

172 **Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma**
F. Dammacco, G. Castoldi and S. Rödjer

180 **Screening for *Aspergillus* spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies**
C. Lass-Flörl, J. Aigner, E. Gunsilius, A. Petzer, D. Nachbaur, G. Gastl, H. Einsele, J. Löffler, M. P. Dierich and R. Würzner

Short reports

185 **Treatment of refractory T-cell malignancies using gemcitabine**
S. Sallah, J. Y. Wan and N. P. Nguyen

188 **Human herpesvirus 8 DNA sequences are present in bone marrow from HIV-negative patients with lymphoproliferative disorders and from healthy donors**
A. Azzi, R. Fanci, R. De Santis, S. Ciappi and C. Paci

191 **High-grade lymphoma mimicking bone crisis in Gaucher's disease**
M. Manz, R. Riessen, L. Poll, B. Dohmen, E. Kaiserling, W. Krück, M. Laniado, L. Kanz and C. Denzlinger

TRANSPLANTATION

194 **Health and functional status of adult recipients 1 year after allogeneic haematopoietic stem cell transplantation**
G. Socié, J.-Y. Mary, H. Esperou, D. V. Robert, S. Aractingi, P. Ribaud, A. Devergie, M.-E. Toubert, P. Boudou, B. Cathelinau, E. Gluckman and P. Vexiau

202 **Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma**
C. I. Chen, M. Crump, R. Tsang, A. K. Stewart and A. Keating

209 **Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–1993 and 1994–1998 at European Group for Blood and Marrow Transplantation centres**
G. Gahrton, H. Svensson, M. Cavo, J. Apperley, A. Bacigalupo, B. Björkstrand, J. Bladé, J. Cornelissen, A. de Laurenzi, T. Facon, P. Ljungman, M. Michallet, D. Niederwieser, R. Powles, J. Reiffers, N. H. Russell, D. Samson, U. W. Schaefer, A. Schattenberg, S. Tura, L. F. Verdonck, J. P. Vernant, R. Willemze and L. Volin for the European Group for Blood and Marrow Transplantation

217 **Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis**
S. Durrant, P. Mollee, A. J. Morton and I. Irving

224 **Changes in the pattern of TCR Vβ repertoire expression after bone marrow transplant is linked to the HLA haplotype in humans**
S. Lonial, C. Bomberger and E. K. Waller

231 ***Ex vivo* generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells**
A. Kleihauer, U. Grigoleit, H. Hebart, A. Moris, P. Brossart, A. Muhm, S. Stevanovic, H. G. Rammensee, C. Sinzger, S. Riegler, G. Jahn, L. Kanz and H. Einsele

240 **Decreased yield, phenotypic expression and function of immature monocyte-derived dendritic cells in cord blood**
E. Liu, W. Tu, H. K. W. Law and Y.-L. Lau

Short reports

247 **Association between the *SDF1-3'A* allele and high levels of CD34+ progenitor cells mobilized into peripheral blood in humans**
L. Benboubker, H. Watier, A. Carion, M.-T. Georget, I. Desbois, P. Colombat, P. Bardos, C. Binet and J. Domenech

251 **Graft-versus-host disease and survival after ABO-incompatible allogeneic bone marrow transplantation: a single-centre experience**
G. Stussi, L. Seebach, J. Muntwyler, U. Schanz, J. Gmür and J. D. Seebach

CORRESPONDENCE

254 **TEL/AML1 fusion is not a prognostic factor in Dutch childhood acute lymphoblastic leukaemia**
I. Hubeek, N. L. Ramakers-van Woerden, R. Pieters, R. Slater, H. B. Beverloo, E. R. van Wering, W. Kamps, K. Hählen and A. J. P. Veerman

255 **Will the high rates of post-treatment sexual stage parasitaemia seen in malaria-endemic areas make the OptiMAL antigen test unreliable in predicting malaria treatment outcome?**
E. Tjitra and N. M. Anstey

257 **Reply to Tjitra and Anstey**
A. H. Moody and P. L. Chiodini

257 **Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide**
V. Mathews, P. Balasubramanian, Shaji R. V., B. George, M. Chandy and A. Srivastava

Volume 113, Issue 2, May 2001

IMAGES IN HAEMATOLOGY

259 **Osteoclasts in Paget's disease of bone**
P. Ganly and M. Beard

260 **Pure red cell aplasia associated with small lymphocytic lymphoma**
R. Cobcroft

ANNOTATION

261 **Woolf, the adversarial system and the concept of blame**
A. Campbell-Tiech

REVIEWS

265 **CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies**
P. Fiumara and A. Younes

275 **ALK$^+$ CD30$^+$ lymphomas: a distinct molecular genetic subtype of non-Hodgkin's lymphoma**
S. W. Morris, L. Xue, Z. Ma and M. C. Kinney

HAEMATOLOGICAL MALIGNANCY

296 **Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor**
E. S. J. M. de Bont, S. Rosati, S. Jacobs, W. A. Kamps and E. Vellenga

305 **Spectral karyotyping and fluorescence *in situ* hybridization detect novel chromosomal aberrations, a recurring involvement of chromosome 21 and amplification of the *MYC* oncogene in acute myeloid leukaemia M2**
E. Hilgenfeld, H. Padilla-Nash, N. McNeill, T. Knutsen, C. Montagna, J. Tchinda, J. Horst, W.-D. Ludwig, H. Serve, T. Büchner, W. E. Berdel, E. Schröck and T. Ried

318 **Unusual T-cell receptor-δ gene rearrangement patterns revealed by screening of a large series of childhood acute lymphoblastic leukaemia by multiplex polymerase chain reaction**
K. Seeger, T. Taube, C. Eckert, C. Hanel, M. Pogodda and G. Henze

323 ***INK4A/ARF* deletions are acquired at relapse in childhood acute lymphoblastic leukaemia: a paired study on 25 patients using real-time polymerase chain reaction**
T. L. Carter, G. H. Reaman and U. R. Kees

329 **Hypermethylation of the calcitonin gene in acute lymphoblastic leukaemia is associated with unfavourable clinical outcome**
J. Roman, J. A. Castillejo, A. Jimenez, R. Bornstein, M. G. Gonzalez, M. del Carmen Rodriguez, M. Barrios, J. Maldonado and A. Torres

339 **Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide**
K. Lotfi, E. Månsson, J. Chandra, Y. Wang, D. Xu, E. Knaust, T. Spasokoukotskaja, E. Liliemark, S. Eriksson and F. Albertioni

347 **The prognostic impact of karyotypic subgroups in myelodysplastic syndromes is strongly modified by sex**
N. Mauritzson, B. Johansson, L. Rylander, M. Albin, U. Strömberg, R. Billström, T. Ahlgren, Z. Mikoczy, F. Mitelman, L. Hagmar and P. G. Nilsson

357 **Mutation analysis of *C-KIT* in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis**
R. Fritsche-Polanz, J.-H. Jordan, A. Feix, W. R. Sperr, G. Sunder-Plassmann, P. Valent and M. Födinger

365 **Fluorescence *in situ* hybridization analysis of 25 cases of idiopathic myelofibrosis and two cases of secondary myelofibrosis: monoallelic loss of RB1, D13S319 and D13S25 loci associated with cytogenetic deletion and translocation involving 13q14**
E. J. Sinclair, E. C. Forrest, J. T. Reilly, A. E. Watmore and A. M. Potter

369 **Technetium-99m-sestamethoxyisobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression, multidrug resistance-related protein expression and other prognosis factors**
C.-H. Kao, S.-C. Tsai, J.-J. Wang, Y.-J. Ho, S.-T. Ho and S.-P. Changlai

375 **A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303**
Y. Yamada, M. Tomonaga, H. Fukuda, S. Hanada, A. Utsunomiya, M. Tara, M. Sano, S. Ikeda, K. Takatsuki, M. Kozuru, K. Araki, F. Kawano, M. Niimi, K. Tobinai, T. Hotta and M. Shimoyama and other members of the Lymphoma Study Group of the Japan Clinical Oncology Group (1994–1996)

383 ***bcl-2* expression in non-Hodgkin's lymphomas is not associated with *bcl-2* gene rearrangements**
G. Papakonstantinou, C. Verbeke, J. Hastka, M. Bohrer and R. Hehlmann

391 **Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia**
M. R. Ricciardi, M. T. Petrucci, C. Gregorj, C. Ariola, R. M. Lemoli, M. Fogli, F. R. Mauro, R. Cerretti, R. Foà, F. Mandelli and A. Tafuri

400 **Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia**
O. Bairey, Y. Zimra, M. Shaklai and E. Rabizadeh

407 **Anticipation in familial chronic lymphocytic leukaemia**
P. H. Wiernik, M. Ashwin, X.-P. Hu, E. Paietta and K. Brown

415 **Microvessel overexpression of aquaporin 1 parallels bone marrow angiogenesis in patients with active multiple myeloma**
A. Vacca, A. Frigeri, D. Ribatti, G. Paola Nicchia, B. Nico, R. Ria, M. Svelto and F. Dammacco

Short reports

422 **Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas**
J. Bladé, M. Perales, L. Rosiñol, M. Tuset, S. Montoto, J. Esteve, F. Cobo, L. Villela, M. Rafel, B. Nomdedeu and E. Montserrat

425 **Post renal transplantation human herpesvirus 8-associated lymphoproliferative disorder and Kaposi's sarcoma**
J. Kapelushnik, S. Ariad, D. Benharroch, D. Landau, A. Moser, G. Delsol and P. Brousset

429 **Marked decrease in the Epstein-Barr virus positivity rate in nodular sclerosis subtype Hodgkin's disease in Tokyo: trend between 1955 and 1999**
K. Takeuchi, Y. Morishita, M. Fukayama and S. Mori

432 **Diffuse large B-cell non-Hodgkin's lymphoma in a patient with autoimmune lymphoproliferative syndrome**
E. Boulanger, F. Rieux-Laucat, C. Picard, M. Legall, F. Sigaux, J.-P. Clauvel, E. Oksenhendler, F. Le Deist and V. Meignin

435 **Molecular cytogenetic characterization of an acquired minute supernumerary marker chromosome as the sole abnormality in a case clinically diagnosed as atypical Philadelphia-negative chronic myelogenous leukaemia**
H. Starke, M. Raida, V. Trifonov, J. H. Clement, I. F. Loncarevic, A. Heller, C. Bleck, A. Nietzel, N. Rubtsov, U. Claussen and T. Liehr

439 **Variant Philadelphia translocations in chronic myeloid leukaemia can mimic typical blast crisis chromosome abnormalities or classical t(9;22): a report of two cases**
A. Reid, S. M. Gribble, B. J. P. Huntly, K. M. Andrews, L. Campbell, C. D. Grace, M. E. Wood, A. R. Green and E. P. Nacheva

443 **Long-term outcome of patients surviving for more than ten years following treatment for acute leukaemia**
I. N. M. Micallef, A. Z. S. Rohatiner, M. Carter, M. Boyle, S. Slater, J. A. L. Amess and T. A. Lister

TRANSPLANTATION

446 **Older patients with high-risk fungal infections can be successfully allografted**

using non-myeloablative conditioning in combination with intensified supportive care regimens
S. Hermann, S. A. Klein, V. Jacobi, A. Thalhammer, H. Bialleck, M. Duchscherer, B. Wassmann, D. Hoelzer and H. Martin

455 **A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2**
J. L. Schultze, K. C. Anderson, M. H. Gilleece, J. G. Gribben and L. M. Nadler

461 **A proposed objective way to assess results of randomized prospective clinical trials with acute graft-versus-host disease as an outcome of interest**
H. Al-Ghamdi, W. Leisenring, W. I. Bensinger, R. A. Nash, R. Storb, F. R. Applebaum and P. J. Martin

470 **Apoptosis and megakaryocytic differentiation during *ex vivo* expansion of human cord blood CD34$^+$ cells using thrombopoietin**
K.-H. Ryu, S. Chun, S. Carbonierre, S.-A. Im, H.-L. Kim, M. H. Shin, H.-Y. Shin, H.-S. Ahn, S.-Y. Woo, J.-Y. Seoh and J. K. Fraser

Short reports

479 **Selective *ex-vivo* expansion of cytomegalovirus-specific CD4$^+$ and CD8$^+$ T lymphocytes using dendritic cells pulsed with a human leucocyte antigen A*0201-restricted peptide**
A. M. Vannucchi, S. Glinz, A. Bosi, R. Caporale and P. Rossi-Ferrini

483 **Immune neutropenia associated with anti-human neutrophil antigen-2a (NB1) antibodies following unrelated donor stem cell transplantation for chronic myeloid leukaemia: perpetuation by granulocyte colony-stimulating factor**
C. F. Pocock, G. F. Lucas, C. Giles, G. Vassiliou, K. Cwynarski, K. Rezvani, J. F. Apperley and J. M. Goldman

ERYTHROCYTES

486 **Oxidative stress and erythrocyte damage in Kenyan children with severe *Plasmodium falciparum* malaria**
M. J. Griffiths, F. Ndungu, K. L. Baird, D. P. R. Muller, K. Marsh and C. R. J. C. Newton

492 **Growth of *Plasmodium falciparum* induces stage-dependent haemichrome formation, oxidative aggregation of band 3, membrane deposition of complement and antibodies, and phagocytosis of parasitized erythrocytes**
G. Giribaldi, D. Ulliers, F. Mannu, P. Arese and F. Turrini

500 **Resveratrol, a natural dietary phytoalexin, possesses similar properties to hydroxyurea towards erythroid differentiation**
C. M. Rodrigue, N. Arous, D. Bachir, J. Smith-Ravin, P.-H. Romeo, F. Galacteros and M.-C. Garel

508 **A novel mutation in the *SLC19A2* gene in a Tunisian family with thiamine-responsive megaloblastic anaemia, diabetes, and deafness syndrome**
S. Gritli, S. Omar, E. Tartaglini, S. Guannouni, J. C. Fleming, M. P. Steinkamp, C. I. Berul, R. Hafsia, S. Baltagi-Ben Jilani, A. Belhani, M. Hamdi and E. J. Neufeld

PLATELETS, HAEMOSTASIS AND THROMBOSIS

514 **Platelet tests in the prediction of myocardial infarction and ischaemic stroke: evidence from the Caerphilly Prospective Study**
P. C. Elwood, A. Beswick, J. Pickering, P. McCarron, J. R. O'Brien, S. R. Renaud and R. J. Flower

521 **Endothelial cell prostacyclin synthesis induced by lymphocytes is independent of the membrane fatty acid composition of both cell types and of E-selectin, VCAM-1 or ICAM-1-mediated adhesion**
Z. Dominguez, F. Merhi-Soussi, O. Macovschi, G. Némoz, M. Lagarde and A.-F. Prigent

533 **Potency estimation of recombinant factor VIII: effect of assay method and standard**
A. R. Hubbard, S. A. Bevan and L. J. Weller

537 **Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis**
A. Amini-Nekoo, T. S. Futers, M. Moia, P. M. Mannucci, P. J. Grant and R. A. S. Ariëns

544 **Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome**
S. Donohoe, I. J. Mackie, D. Isenberg and S. J. Machin

Short reports

550 **Antibodies to factor XII and recurrent fetal loss in patients with the anti-phospholipid syndrome**
D. W. Jones, I. J. Mackie, M. J. Gallimore and M. Winter

553 **The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden**
S. Middeldorp, E. J. Libourel, K. Hamulyák, J. van der Meer and H. R. Büller

TRANSFUSION MEDICINE

Short report

556 **Incidence and associations of acute renal failure complicating high-dose intravenous immunoglobulin therapy**
H. I. A. Sati, R. Ahya and H. G. Watson

CORRESPONDENCE

558 **Following the course of malaria treatment by detecting parasite lactate dehydrogenase enzyme**
R. Scott Miller, P. McDaniel and C. Wongsrichanalai

559 **Thrombolysis failure: a role for plasminogen activator inhibitor type I**
S. C. Nicholls, W. L. Chandler and E. K. Hoffer

560 **Potential strategies for the treatment of plasma exchange-resistant thrombotic thrombocytopenic purpura**
G. Quintini, V. Barbera, E. Iannitto and G. Mariani

561 **Reply to Quintini *et al***
G. Rock

563 **ERRATUM**

563 **ANNOUNCEMENT**

Volume 113, Number 3, June-I 2001

IMAGES IN HAEMATOLOGY

565 **Angiogenesis in multiple myeloma**
S. V. Rajkumar and P. R. Greipp

566 **Disseminated *Mycobacterium avium intracellulare* infection in a patient with AIDS**
M. H. Bañas Llanos and C. Salas Antón

REVIEW

567 **The hepatologist in the haematologists' camp**
C. Liatsos, A. B. Mehta, M. Potter and A. K. Burroughs

HISTORICAL REVIEW

579 **The history of folic acid**
A. V. Hoffbrand and D. G. Weir

PLATELETS, HAEMOSTASIS AND THROMBOSIS

590 **Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis**
L. E. Adinolfi, M. G. Giordano, A. Andreana, M.-F. Tripodi, R. Utili, G. Cesaro, E. Ragone, E. D. Mangoni and G. Ruggiero

596 **Polymorphisms in inflammatory cytokines and Fcγ receptors in childhood chronic immune thrombocytopenic purpura: a pilot study**
C. B. Foster, S. Zhu, H. C. Erichsen, T. Lehrnbecher, E. S. Hart, E. Choi, S. Stein, M. W. Smith, S. M. Steinberg, P. Imbach, T. Kühne and S. J. Chanock for the Early Chronic ITP Study Group

600 **Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age**
J. I. Lorenzo, A. López, C. Altisent and J. A. Aznar

604 **Stable recombinant expression and characterization of the two haemophilic factor VIII variants C329S (CRM^-) and G1948D (CRM^r)**
D. David, E. L. Saenko, I. M. A. Santos, D. J. D. Johnson, E. G. D. Tuddenham, J. H. McVey and G. Kemball-Cook

616 **Deletion of the factor IX gene as a result of translocation t(X;1) in a girl affected by haemophilia B**
A. C. V. Krepischi-Santos, J. D. A. Carneiro, M. Svartman, I. Bendit, V. Odone-Filho and A. M. Vianna-Morgante

621 **Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces**
M. J. A. Simmelink, D. A. Horbach, R. H. W. M. Derksen, J. C. M. Meijers, E. M. Bevers, G. M. Willems and P. G. de Groot

630 **The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation**
V. De Stefano, I. Martinelli, P. M. Mannucci, K. Paciaroni, E. Rossi, P. Chiusolo, I. Casorelli and G. Leone

636 **A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state**
A. C. Dykes, I. D. Walker, A. D. McMahon, S. I. A. M. Islam and R. C. Tait

642 **Symptomatic type 1 protein C deficiency caused by a *de novo* Ser270Leu mutation in the catalytic domain**
B. Lind, P. Koefoed and S. Thorsen

Short reports

649 **Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease**
J. Barbot, E. Costa, M. Guerra, M. S. Barreirinho, P. Isvarlal, R. Robles, H. E. Gerritsen, B. Lämmle and M. Furlan

652 **Novel Y283C mutation of the A subunit for coagulation factor XIII: molecular modelling predicts its impaired protein folding and dimer formation**
M. Souri, V. C. Yee, K. Kasai, T. Kaneshiro, K. Narasaki, G. Castaman and A. Ichinose

655 **High concentrations of coagulation factor VIII and thrombosis: is the factor VIII-binding domain of von Willebrand factor implicated?**
D. J. Bowen, R. M. Maclean, S. Pellard and P. W. Collins

658 **Chronic disseminated intravascular coagulation after surgery for abdominal aortic aneurysm: clinical and haemostatic response to dalteparin**
D. Cummins, H. Segal, B. J. Hunt, R. Awad and A. Maddox

TRANSFUSION MEDICINE

661 **Red cell antibodies in patients with homozygous sickle cell disease: a comparison of patients in Jamaica and the United Kingdom**
A. Olujohungbe, I. Hambleton, L. Stephens, B. Serjeant and G. Serjeant

666 **16Cys encoded by the *RHce* gene is associated with altered expression of the e antigen and is frequent in the R_0 haplotype**
C. M. Westhoff, L. E. Silberstein, D. E. Wylie, M. Skavdahl and M. E. Reid

672 **Two new alleles of the *RHCE* gene in Black individuals: the *RHce* allele *ceMO* and the *RHcE* allele *cEMI***
F. Noizat-Pirenne, I. Mouro, P.-Y. Le Pennec, H. Ansart-Pirenne, G. Juszczak, C. Patereau, M. Verdier, J. Babinet, M. Roussel, P. Rouger and J.-P. Cartron

680 **Flow cytometric analysis of the association between blood group-related proteins and the detergent-insoluble material of K562 cells and erythroid precursors**
P. Gane, C. Le Van Kim, V. Bony, W. El Nemer, I. Mouro, V. Nicolas, Y. Colin and J.-P. Cartron

ERYTHROCYTES

689 **Band 3 Cape Town (E90K) causes severe hereditary spherocytosis in combination with band 3 Prague III**
N. A. Bracher, C. A. Lyons, G. Wessels, E. Mansvelt and T. L. Coetzer

Short report 694 **Polymerase chain reaction protocols for alpha globin haplotype polymorphisms**
K. L. Miles, J. T. Norwich, J. J. Martinson and J. B. Clegg

LEUCOCYTES

699 **Lack of CD40-dependent B-cell proliferation in B lymphocytes isolated from patients with persistent polyclonal B-cell lymphocytosis**
M. M. Loembé, J. Lamoureux, N. Deslauriers, A. Darveau and R. Delage

BONE MARROW FAILURE

706 **Bcl-2 and Bcl-x expression in the $CD34^+$ cells of aplastic anaemia patients: relationship with increased apoptosis and upregulation of Fas antigen**
M. Ismail, F. M. Gibson, E. C. Gordon-Smith and T. R. Rutherford

HAEMATOLOGICAL MALIGNANCY

713 **Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial**
J. A. Liu Yin, K. Wheatley, J. K. H. Rees and A. K. Burnett on behalf of the UK MRC Adult Leukaemia Working Party

727 **Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia**
J. P. Matthews, J. F. Bishop, G. A. R. Young, S. K. Juneja, R. M. Lowenthal, O. M. Garson, R. G. Cobcroft, A. J. Dodds, A. Enno, E. A. Gillett, R. P. Hermann, D. E. Joshua, D. D. Ma, J. Szer, K. M. Taylor, M. Wolf and K. F. Bradstock for the Australian Leukaemia Study Group

737 **Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients**
M.-C. Béné, M. Bernier, R. O. Casasnovas, G. Castoldi, D. Doekharan, B. van der Holt, W. Knapp, P. Lemež, W.-D. Ludwig, E. Matutes, A. Orfao, C. Schoch, C. Sperling and M. B. van't Veer for the European Group for the Immunological Characterization of Leukaemias (EGIL)

746 **Relationship of p15 and p16 gene alterations to elevated dihydrofolate reductase in childhood acute lymphoblastic leukaemia**
S. J. Shah, J. W. Taub, T. L. Witt, B. H. Pollock, B. C. Ding, D. S. Moore, M. Amylon, J. Pullen, Y. Ravindranath and L. H. Matherly

757 **Two consecutive immunophenotypic switches in a child with immunogenotypically stable acute leukaemia**
M. Bierings, T. Szczepański, E. R. van Wering, M. J. Willemse, A. W. Langerak, T. Révész and J. J. M. van Dongen

763 **Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia**
A. Tefferi, R. A. Mesa, G. Schroeder, C. A. Hanson, C.-Y. Li and G. W. Dewald

772 **Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma**
C. Dumontet, F. Morschhauser, P. Solal-Celigny, F. Bouafia, E. Bourgeois, C. Thieblemont, X. Leleu, O. Hequet, G. Salles and B. Coiffier

779 **Interferon α and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients**
E. Matutes, G. P. Taylor, J. Cavenagh, A. Pagliuca, D. Bareford, A. Domingo, M. Hamblin, S. Kelsey, N. Mir and J. T. Reilly

785 **Class switch recombination was specifically targeted to immunoglobulin (Ig)G4 or IgA in Hodgkin's disease-derived cell lines**
J. Irsch, J. Wolf, H. Tesch, V. Diehl, A. Radbruch and A. Staratschek-Jox

794 **In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA-5 and CD45 expression**
A. C. Rawstron, S. L. Barrans, D. Blythe, A. English, S. J. Richards, J. A. L. Fenton, F. E. Davies, J. A. Child, A. S. Jack and G. J. Morgan

Short report 803 **Detection of reciprocal fusion 5′-*BCL6*/partner-3′ transcripts in lymphomas exhibiting reciprocal *BCL6* translocations**
Y. Kaneita, S. Yoshida, N. Ishiguro, U. Sawada, T. Horie, S. Mori and M. Moriyama

TRANSPLANTATION

807 **Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants**
H. Cullup, A. M. Dickinson, G. H. Jackson, P. R. Taylor, J. Cavet and P. G. Middleton

814 **Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein–Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation**
J. W. J. van Esser, H. G. M. Niesters, S. F. T. Thijsen, E. Meijer, A. D. M. E. Osterhaus, K. C. Wolthers, C. A. B. Boucher, J. W. Gratama, L. M. Budel, B. van der Holt, A. M. van Loon, B. Löwenberg, L. F. Verdonck and J. J. Cornelissen

822 **Effect of chemotherapy and stem cell transplantation on T lymphocyte clones in familial haemophagocytic lymphohistiocytosis**
N. Kimura, E. Ishii, M. Sako, T. Yoshida, M. Nagano, H. Takada, S. Imashuku and K. Tamura

Short reports

832 **Changes in the expression of *FGFR3* in patients with chronic myeloid leukaemia receiving transplants of allogeneic peripheral blood stem cells**
D. Dvorakova, P. Krejci, J. Mayer, J. Fajkus, A. Hampl and P. Dvorak

836 **Non-transferrin-bound iron during allogeneic stem cell transplantation**
L. Sahlstedt, F. Ebeling, L. von Bonsdorff, J. Parkkinen and T. Ruutu

CORRESPONDENCE

839 **The use of oral vitamin K for reversal of over-warfarinization**
K. Pendry, M. Bhavnani and K. Shwe

840 **Autologous stem cell transplantation for rapidly progressive JO-1-positive polymyositis with long-term follow-up**
S. Bingham, B. Griffiths, D. McGonagle, J. A. Snowden, G. Morgan and P. Emery

841 **Bisphosphonates and *in vivo* models of multiple myeloma**
M. Salomo and P. Gimsing

842 **Reply to Salomo and Gimsing**
C. M. Shipman, P. I. Croucher and K. Vanderkerken

843 **BOOK REVIEW**

844 **ERRATA**

844 **ANNOUNCEMENT**

Volume 113, Issue 4, June-II 2001

IMAGES IN HAEMATOLOGY

845 **Erythrophagocytosis associated with AML-M5 and t(8;16)**
C. H. Hui and J. Suttle

846 **Acute cerebellar syndrome following intermediate-dose cytarabine**
M. Yeshurun and K. Marsot Dupuch

REVIEW

847 **Near-patient testing devices to monitor oral anticoagulant therapy**
A. Tripodi, V. Chantarangkul and P.M. Mannucci

HISTORICAL REVIEW

853 **Origins of the discipline 'Neonatal Haematology', 1925–75**
R. D. Christensen

PLATELETS, HAEMOSTASIS AND THROMBOSIS

861 **Protein assays for diagnosis of Wiskott–Aldrich syndrome and X-linked thrombocytopenia**
W. Qasim, K. C. Gilmour, S. Heath, E. Ashton, T. Cranston, A. Thomas, A. Finn, E. G. Davies, A. J. Thrasher, C. Kinnon, A. Jones and H. B. Gaspar

866 **Congenital thrombocytopenia and radio-ulnar synostosis: a new familial syndrome**
A. A. Thompson, K. Woodruff, S. A. Feig, L. T. Nguyen and N. C. Schanen

871 **The storage defects in grey platelet syndrome and αδ-storage pool deficiency affect α-granule factor V and multimerin storage without altering their proteolytic processing**
C. P. M. Hayward, H. J. Weiss, B. Lages, M. Finlay, A.-C. Hegstad, S. Zheng, A. Cowie, J.-M. Massé, P. Harrison and E. M. Cramer

878 **Characterization of a partial prostaglandin endoperoxide H synthase-1 deficiency in a patient with a bleeding disorder**
J.-N. Dubé, J. Drouin, M. Aminian, M. H. Plant and O. Laneuville

886 **Determination of heparin–platelet factor 4–IgG antibodies improves diagnosis of heparin-induced thrombocytopenia**
E. Lindhoff-Last, F. Gerdsen, H. Ackermann and R. Bauersachs

891 **Interaction of cytokines and growth factor in the regulation of verotoxin-induced apoptosis in cultured human endothelial cells**
G. Molostvov, A. Morris, P. Rose and S. Basu

898 **Protein S levels are lower in women receiving desogestrel-containing combined oral contraceptives (COCs) than in women receiving levonorgestrel-containing COCs at steady state and on cross-over**
I. J. Mackie, K. Piegsa, S.-A. Furs, J. Johnson, W. Bounds, S. J. Machin and J. Guillebaud

905 **Increased activation of protein C, but lower plasma levels of free, activated protein C in uraemic patients: relationship with systemic inflammation and haemostatic activation**
D. Mezzano, F. España, O. Panes, P. Medina, E. Pais, G. Marshall, R. Tagle, P. Downey, S. Caceres, F. González, T. Quiroga and J. Pereira

911 **Anti-beta 2 glycoprotein 1 and anti-annexin V antibodies in women with recurrent miscarriage**
J. Arnold, Z. Holmes, W. Pickering, C. Farmer, L. Regan and H. Cohen

915 **Epitope mapping of factor VIII inhibitor antibodies of Chinese origin**
C.-C. Huang, M.-C. Shen, J.-Y. Chen, M.-H. Hung, T.-C. Hsu and S.-W. Lin

LEUCOCYTES

925 **Identification of both myeloid CD11c$^+$ and lymphoid CD11c$^-$ dendritic cell subsets in cord blood**
F. E. Borràs, N. C. Matthews, M. W. Lowdell and C. V. Navarrete

ERYTHROCYTES

932 **Two further British families with the 'cryohydrocytosis' form of hereditary stomatocytosis**
P. G. Haines, H. G. Jarvis, S. King, F. H. Noormohamed, M. C. Chetty, J. Fisher, P. Hill, A. Nicolaou and G. W. Stewart

Short report 938 **Congenital sideroblastic anaemia successfully treated using allogeneic stem cell transplantation**
M. Ayas, A. Al-Jefri, M. M. Mustafa, M. Al-Mahr, L. Shalaby and H. Solh

HAEMOPOIESIS

940 **Irradiation enhances the support of haemopoietic cell transmigration, proliferation and differentiation by endothelial cells**
M.-H. Gaugler, C. Squiban, M.-A. Mouthon, P. Gourmelon and A. Van der Meeren

951 **Accumulation of γ-globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallimustine**
N. Bianchi, C. Chiarabelli, M. Borgatti, C. Mischiati, E. Fibach and R. Gambari

962 **Short-term phytohaemagglutinin-activated mononuclear cells induce endothelial progenitor cells from cord blood CD34$^+$ cells**
H. J. Kang, S. C. Kim, Y. J. Kim, C. W. Kim, J. G. Kim, H. S. Ahn, S. I. Park, M. H. Jung, B. C. Choi and K. Kimm

970 **A cautionary tale: how to delete mouse haemopoietic stem cells with busulphan**
C. Jopling and M. Rosendaal

HAEMATOLOGICAL MALIGNANCY

975 **Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia**
J. Braess, G. Jahns-Streubel, C. Schoch, D. Haase, T. Haferlach, M. Fiegl, S. Voss, W. Kern, E. Schleyer and W. Hiddemann

983 **Identification of novel *FLT-3* Asp835 mutations in adult acute myeloid leukaemia**
F. M. Abu-Duhier, A. C. Goodeve, G. A. Wilson, R. S. Care, I. R. Peake and J. T. Reilly

989 **Intercellular adhesion molecule-1 in extravasation of normal mononuclear and leukaemia cells**
S. Mustjoki, R. Alitalo, E. Elonen, O. Carpén, C. G. Gahmberg and A. Vaheri

1001 **Analysis of Vγ/Jβ *trans*-rearrangements in paediatric patients undergoing chemotherapy**
L. F. Lopes, E. D. Neto, I. Lorand-Metze, M. do R. D. O. Latorre and A. J. G. Simpson

1009 ***In vitro* induction of apoptosis for nasal angiocentric natural killer cell lymphoma-derived cell line, NK-YS, by etoposide and cyclosporine A**
M. Uno, J. Tsuchiyama, A. Moriwaki, T. Noguchi, K. Mizoguchi, T. Ogino, T. Yoshino, S. Okada and M. Harada

1015 **Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma**
F. C. Sampson, S. M. Beard, F. Scott and E. Vandenberghe

1020 **Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients**
The Myeloma Trialists' Collaborative Group

1035 **Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma**
E. V. McCloskey, J. A. Dunn, J. A. Kanis, I. C. M. MacLennan and M. T. Drayson on behalf of the Medical Research Council Working Party on Leukaemia in Adults

Short reports

1044 **A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis**
G. Palladini, E. Anesi, V. Perfetti, L. Obici, R. Invernizzi, C. Balduini, E. Ascari and G. Merlini

1047 **True histiocytic lymphoma following B-acute lymphoblastic leukaemia: case report with evidence for a common clonal origin in both neoplasms**
R. Bouabdallah, P. Abéna, B. Chetaille, T. Aurran-Schleinitz, D. Sainty, P. Dubus, C. Arnoulet, D. Coso, L. Xerri and J.-A. Gastaut

TRANSPLANTATION

1051 **Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion**
S. Mariani, M. Coscia, J. Even, S. Peola, M. Foglietta, M. Boccadoro, L. Sbaiz, G. Restagno, A. Pileri and M. Massaia

1060 **Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant *in vivo* T-cell depletion with anti-thymocyte globulin**

N. Kröger, T. Zabelina, W. Krüger, H. Renges, N. Stute, J. Schrum, H. Kabisch, P. Schafhausen, N. Jaburg, C. Löliger, P. Schäfer, A. Hinke and A. R. Zander

Short report 1072 **Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of BCR-ABL fusion transcripts as detected using a new real-time polymerase chain reaction method**
A. H. Elmaagacli, A. Freist, M. Hahn, B. Opalka, S. Seeber, U. W. Schaefer and D. W. Beelen

CORRESPONDENCE

1076 **Genomic structure of human *FLT3*: implications for mutational analysis**
F. M. Abu-Duhier, A. C. Goodeve, G. A. Wilson, R. S. Care, I. R. Peake and J. T. Reilly

1077 **Serendipity and the use of random donor platelets in fetomaternal alloimmune thrombocytopenia (FMAIT)**
M. F. Murphy, C. Knechtli, C. Downie, S. E. Rogers and G. F. Lucas

1078 **Priming of neutrophil function in the newborn**
M. S. Jaswon and D. C. Linch

1079 **Reply to Jaswon and Linch**
R. Carr

1079 ***TEL/MN1* fusion in a *de novo* acute myeloid leukaemia-M2 patient who showed strong resistance to treatment**
H. Nakazato, H. Shiozaki, M. Zhou, M. Nakatsu, T. Motoji, H. Mizoguchi, S. Miyawaki and Y. Sato

1081 **The contribution of F. W. Peabody to the study of pernicious anaemia**
I. Krsnik

1082 **Low frequency of reverse transcription polymerase chain reaction-detectable chromosome aberrations in relapsed acute myeloid leukaemia: implications for detection of minimal residual disease**
V. H. J. van der Velden, C. Schoch, A. W. Langerak, S. Schnittger, P. G. Hoogeveen and J. J. M. van Dongen

1083 **Antenatal testing for haemoglobinopathies**
B. J. Bain, R. J. Amos, D. Bareford, C. Chapman, S. C. Davies, J. M. Old and B. J. Wild on behalf of the General Haematology Task Force of the British Committee for Standards in Haematology

1084 **Clinical monitoring after cessation of enzyme replacement therapy in M. Gaucher**
S. vom Dahl, L. W. Poll and D. Häussinger

1086 **Reply to vom Dahl *et al***
D. Elstein, A. Abrahamov, I. Hadas-Halpern and A. Zimran

1087 **Interruption in enzyme replacement therapy for Gaucher disease**
N. J. Weinreb

1088 **Reply to Weinreb**
D. Elstein, A. Aya, I. Hadas-Halpern and A. Zimran

1089 **Effects of imilglucerase withdrawal on an adult with Gaucher disease**
I. V. D. Schwartz, S. Karam, P. Ashton-Prolla, K. Michelin, J. Coelho, R. F. Pires, M. L. Pereira and R. Giugliani

1090 **BOOK REVIEW**

1091 **AUTHOR AND KEYWORD INDEXES TO VOLUME 113**